Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials.

Wilkes MM, Navickis RJ, Chan WW, Lewiecki EM.

Osteoporos Int. 2010 Apr;21(4):679-88. doi: 10.1007/s00198-009-0991-1. Epub 2009 Jul 2. Review.

PMID:
19572092
2.

Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women.

Ellis AG, Reginster JY, Luo X, Bushmakin AG, Williams R, Sutradhar S, Mirkin S, Jansen JP.

Curr Med Res Opin. 2014 Aug;30(8):1617-26. doi: 10.1185/03007995.2014.908279. Epub 2014 May 2. Review.

PMID:
24773456
3.

Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries.

Wang Z, Ward MM, Chan L, Bhattacharyya T.

Osteoporos Int. 2014 Aug;25(8):2109-16. doi: 10.1007/s00198-014-2738-x. Epub 2014 May 21.

4.

Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis.

Imaz I, Zegarra P, González-Enríquez J, Rubio B, Alcazar R, Amate JM.

Osteoporos Int. 2010 Nov;21(11):1943-51. doi: 10.1007/s00198-009-1134-4. Epub 2009 Dec 5. Review.

PMID:
19967338
5.

Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.

Abelson A, Ringe JD, Gold DT, Lange JL, Thomas T.

Osteoporos Int. 2010 Jun;21(6):1021-9. doi: 10.1007/s00198-009-1046-3. Epub 2009 Sep 1.

6.

Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice.

Thomas T, Horlait S, Ringe JD, Abelson A, Gold DT, Atlan P, Lange JL.

Osteoporos Int. 2013 Jan;24(1):263-9. doi: 10.1007/s00198-012-2060-4. Epub 2012 Jun 27.

PMID:
22736069
7.

Relationship between duration of compliant bisphosphonate use and the risk of osteoporotic fractures .

Meijer WM, Penning-van Beest FJ, Olson M, Herings RM.

Curr Med Res Opin. 2008 Nov;24(11):3217-22. doi: 10.1185/03007990802470241. Epub 2008 Oct 14.

PMID:
18922215
8.

GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates.

Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T.

Osteoporos Int. 2012 Jan;23(1):223-31. doi: 10.1007/s00198-011-1535-z. Epub 2011 Feb 10.

PMID:
21308365
9.

Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.

Lindsay R, Watts NB, Lange JL, Delmas PD, Silverman SL.

Osteoporos Int. 2013 Aug;24(8):2345-52. doi: 10.1007/s00198-013-2332-7. Epub 2013 Apr 24. Erratum in: Osteoporos Int. 2013 Aug;24(8):2375-6.

PMID:
23612793
10.

CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.

Albert SG, Reddy S.

Endocr Pract. 2017 Jul;23(7):841-856. doi: 10.4158/EP161678.RA. Epub 2017 Apr 27. Review.

PMID:
28448754
11.

Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.

Brown JP, Roux C, Ho PR, Bolognese MA, Hall J, Bone HG, Bonnick S, van den Bergh JP, Ferreira I, Dakin P, Wagman RB, Recknor C.

Osteoporos Int. 2014 Jul;25(7):1953-61. doi: 10.1007/s00198-014-2692-7. Epub 2014 Mar 28.

PMID:
24676847
12.

The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis.

Jansen JP, Bergman GJ, Huels J, Olson M.

Semin Arthritis Rheum. 2011 Feb;40(4):275-84.e1-2. doi: 10.1016/j.semarthrit.2010.06.001. Epub 2010 Sep 9.

PMID:
20828791
13.

Bisphosphonates for steroid-induced osteoporosis.

Allen CS, Yeung JH, Vandermeer B, Homik J.

Cochrane Database Syst Rev. 2016 Oct 5;10:CD001347. Review.

PMID:
27706804
14.

Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study.

Silverman SL, Chines AA, Kendler DL, Kung AW, Teglbjærg CS, Felsenberg D, Mairon N, Constantine GD, Adachi JD; Bazedoxifene Study Group.

Osteoporos Int. 2012 Jan;23(1):351-63. doi: 10.1007/s00198-011-1691-1. Epub 2011 Jul 21.

PMID:
21779819
15.

Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.

Cairoli E, Eller-Vainicher C, Ulivieri FM, Zhukouskaya VV, Palmieri S, Morelli V, Beck-Peccoz P, Chiodini I.

Osteoporos Int. 2014 Apr;25(4):1401-10. doi: 10.1007/s00198-014-2619-3. Epub 2014 Feb 8.

PMID:
24510095
16.

Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday.

Curtis JR, Westfall AO, Cheng H, Delzell E, Saag KG.

Osteoporos Int. 2008 Nov;19(11):1613-20. doi: 10.1007/s00198-008-0604-4. Epub 2008 May 16.

17.

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

Chesnut CH 3rd, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE).

J Bone Miner Res. 2004 Aug;19(8):1241-9. Epub 2004 Mar 29.

18.

Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis.

Freemantle N, Cooper C, Diez-Perez A, Gitlin M, Radcliffe H, Shepherd S, Roux C.

Osteoporos Int. 2013 Jan;24(1):209-17. doi: 10.1007/s00198-012-2068-9. Epub 2012 Jul 26.

19.

Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies.

Miller PD, Recker RR, Harris S, Silverman S, Felsenberg D, Reginster J, Day BM, Barr C, Masanauskaite D.

Osteoporos Int. 2014 Jan;25(1):349-57. doi: 10.1007/s00198-013-2518-z. Epub 2013 Oct 18.

PMID:
24136103
20.

Bisphosphonate use and subsequent hip fracture in South Korea.

Lee YK, Ha YC, Choi HJ, Jang S, Park C, Lim YT, Shin CS.

Osteoporos Int. 2013 Nov;24(11):2887-92. doi: 10.1007/s00198-013-2395-5. Epub 2013 May 17.

PMID:
23681088

Supplemental Content

Support Center